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Introduction
Bacterial resistance to antibiotics, first noticed back in the 1950s, is a growing concern for public health. 1 Because of their mechanism of action, the antimicrobial peptides (AMPs) represent an attractive alternative as human therapeutics. AMPs are part of the innate immune system and represent an important component of immune defense. They have a large spectrum of antimicrobial activities against gram-positive and gram-negative bacteria, fungi, 2 and viruses like influenza A 3 or human immunodeficiency virus (HIV-1). 4 Moreover, certain peptides may possess anticancer activity. 5 AMPs are generally defined as cationic, amphipathic peptides, with less than 50 amino acids, including multiple arginine and lysine residues 6 and show inhibitory concentrations (MIC) as low as 0.25-4 lg/ml. 7 They are widely distributed in nature, from insects to plants and animal species; at least 1972 AMPs have been identified so far (http://aps.unmc.edu/AP/main.php; May 2012).
Magainins are AMPs isolated from the skin of the African clawed frog Xenopus laevis. 8, 9 Magainins are comprised of 21-27 amino acid residues that create an a-helical secondary structure characterized by separate cationic and hydrophobic faces. 5 Magainin-2 (GIGKFLHSAKKFGKAFVGEIMNS), a polycationic peptide with a net positive charge of 3, has been well studied for its killing action on various microorganisms, as well as on tumor cells. [10] [11] [12] It acts by permeabilizing their membranes, either in a detergent-like manner or by making well-structured channels. 13, 14 Magainin-2 and its more potent synthetic analogs (magainins A, B, and G) cause the rapid lysis of both hematopoietic and solid tumor cell lines at concentrations 5-to 10-fold lower than those lytic for normal human peripheral blood lymphocytes or neutrophils.
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Many bacterial and fungal enzymes that hydrolyze insoluble carbohydrates share a common structure composed of a catalytic domain linked to a carbohydrate-binding module (CBM). CBMs that are specific for insoluble cellulose (cellulose binding domain-CBD) represent the predominant category. The CBMs can be grouped into distinctive families on the basis of amino acid sequence similarities 15 ; 64 families of CBMs have been recognized so far (http://www.cazy.org/ fam/acc_CBM.html; May 2012).
Family-III CBDs normally comprise $150 amino acids residues, have been identified in many different bacterial enzymes, and also in nonhydrolytic proteins. 16 Clostridium thermocellum produces a multienzyme complex of cellulases and hemicellulases, termed the cellulosome, which is assembled by the scaffoldin protein CipA. Binding of the cellulosome to the plant cell wall is driven by the action of the CipA family 3 CBM (CBM3), which presents high affinity for crystalline cellulose.
17 CBM3 belongs to the all-b family of proteins and is arranged in two antiparallel b sheets that form a b sandwich with jellyroll topology. 16 AMPs have potential to provide an important breakthrough and form the basis for a new class of antibiotics. Since, AMPs are usually short peptides, chemical synthesis could be one approach for producing them. However, a costeffective and scalable method of active production is required in order to commercialize the bacterial peptides. Bacterial expression of heterologs proteins is an easy and inexpensive tool for producing large amounts of recombinant Correspondence concerning this article should be addressed to M. Gama at fmgama@deb.uminho.pt. proteins. 18 Production of recombinant expression of AMPs in Escherichia coli is potentially limited because of their toxicity to host cells and susceptibility to proteolytic degradation, which can be avoided using fusion protein approach. 19 There are several fusion partners (e.g., solubility-enhancing, aggregation-promoting, and self-cleavable carriers, etc), cleavage methods and optimization options for AMPs production in E. coli. 20 However, the very few works describing MAG2 expression in E. coli, including using fusing partners, 21 may indicate that it is very difficult to produce MAG2 in bacteria. As Magainin displays high antibacterial and antitumor activities, 11, 12 the development of a method to obtain recombinant and functional Magainin but at low cost is crucial for its expansion as a therapeutic agent. 18, 19 Moreover, potent analogs of MAG2 have been obtained by substitutions of glycine or serine with alanine residues and amidation of the C-terminus, which resulted in enhanced a-helical structure and antimicrobial activity. Studies with pronase digestion suggested that the lower antimicrobial of MAG2 activity, when comparing to analogs, may be due to higher susceptibility to proteolysis in the presence of membranes. 10 In this work, the fusion of MAG2 with the CBM3 was attempted as an approach for its large scale production and could also be used for the production of Magainin analogs.
Materials and Methods

Construction of expression vectors
The gene encoding CBM3 fused to the endogenous CipA N-terminal linker sequence (LK) has previously been cloned in the expression vector pET-21a (Novagen), in our laboratory. 17 The expression vector was constructed with MAG2 at the N-terminal (MAG2-LK-CBM3) of the pET-21a vector ( Figure 1 ). This vector was constructed to allow the cloning of MAG2 at the N-terminal of the LK-CBM3 while keeping a C-terminal His 6-tag.
The nucleotide sequence of MAG2 was engineered to allow codon optimization in E. coli. The sequence encoding the peptide was included in the primers in fusion with the gene of a family 3 CBM. The pET-21a-LK-CBM3 was used as template. For the MAG2-LK-CBM3 construction, the following primers were used: 5 0 -GGA ATTC CAT ATG GGT ATT GGT AAA TTT CTG CAT AGC GCG AAA AAA TTT GGT AAA GCG TTT GTG GGT GAA ATT ATG AAC AGC GAT CCG ACA CCG ACC AAG GGA GCA-3 0 (forward primer) and 5 0 -CAC CTC GAG TTC TTT ACC CCA TAC AAG AAC-3 0 (reverse primer). NdeI, XhoI (MAG2-LK-CBM3) recognition sites are shown in bold. In order to allow the chemical cleavage with formic acid, proline and aspartate residues were introduced (underlined). PCR reactions were performed using the DNA polymerase VENT (Stratagene). The PCR reactions were performed as follows: preheating at 95 C for 2 min, 30 cycles at 95 C for 30 s, 30 s at 52 C, and 30 s at 72 C, followed by a final elongation stage at 72 C for 10 min. The amplified product was recovered from 1% agarose gel, digested with NdeI and XhoI and ligated into pET-21a plasmids. The plasmid was sequenced to ensure that no mutations had occurred during PCR. Figure 1 represents MAG2-LK-CBM3 construction.
Expression and purification of fusion protein
The recombinant plasmid pET-21a-MAG2-LK-CBM3 was transformed into the E. coli strain BL21 (DE3) (Novagen) for protein expression. The bacterial strain was grown in Luria-Bertani broth (LB) containing 100 lg/ml of ampicillin, at 37 C, to mid-exponential phase (OD 595 0.6). Expression of the fusion protein was initiated by adding isopropylb-D-thiogalactopyranoside (IPTG) at a final concentration of 1 mM and the culture was incubated overnight at 37 C. Then, the cells were centrifuged at 6000 rpm for 15 min at 4 C, resuspended in 150 mM Tris-HCl, pH 7.0, 20 mM NaCl, 5 mM CaCl 2 (2H 2 O) buffer (CBM buffer) and sonicated in ice for 6 min. The cells were centrifuged at 12,000 rpm, for 30 min at 4 C and the soluble fraction was collected.
The His 6-tagged recombinant protein was purified by immobilized metal ion affinity chromatography (IMAC), using 5 ml Niquel His-Trap Columns (GE Health). The column charged with 0.1 M NiSO 4 was equilibrated with 20 mM of Na 3 PO 4 , 500 mM NaCl, 40 mM Imidazole, pH 7.4. The cell extract was loaded into the column, which was washed with the equilibration buffer. Finally, the recombinant protein were eluted with 20 mM Na 3 PO 4 , 500 mM NaCl, 300 mM Imidazole, pH 7.4. After purification, protein buffer was exchanged into CBM buffer, using PD10-columns (GE Health).
The recombinant protein was also purified on cellulose CF11 (Sigma), exploiting the CBM3 cellulose-binding properties, as follows: 20 ml of cell-free extracts were mixed with 2 g of cellulose and incubated, with agitation, for 1 h at 4 C. The cellulose with bound proteins was then centrifuged and washed 5 times with CBM buffer.
Formic acid cleavage and MAG2 purification
To cleave MAG2 of the recombinant protein, a 50% formic acid solution (20 ml of distilled water and 26 ml 88% formic acid) was applied directly to cellulose with the adsorbed fusion protein. In the case of proteins purified by IMAC, formic acid was mixed with the purified protein (20 ml of pure protein and 26 ml of formic acid 88%). The mixture was then incubated for 24 h, at 50 C. The supernatant was separated after centrifugation at 12,000 rpm, for 30 min, and lyophilized to remove formic acid. The cleavage was confirmed by SDS-PAGE using a 16.5% Tris-Tricine gel.
The purification of MAG2 was achieved by reverse-phase HPLC, using an YMC C18 preparative column (250 Â 30 mm) equilibrated with aqueous acetonitrile (5%)/0.1% trifluoracetic acid (TFA). The peptide was eluted using a linear gradient of acetonitrile from 5% to 90% at a flow rate of 5 ml/min. The elution was monitored at 215 nm. Several peaks were collected and analyzed by SDS-PAGE using a 16% Tris-Tricine gel. The fraction corresponding to pure MAG2 was lyophilized.
The purification of MAG2 was also attempted through ultrafiltration in a Centricon with 5 kDa molecular weight cut-off (Millipore). The filtrate was collected and analyzed by 16% Tris-Tricine gel SDS-PAGE. The concentration of the recombinant peptide was quantified using Waddell's method. 
MALDI-TOF mass spectrometry
The formic acid cleavage of the recombinant proteins and the purity of MAG2 were evaluated by mass spectrometry at the Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP). Sample was desalted and concentrated using microC18 ZipTips (Millipore, USA) accordingly to the manufacturer's protocol. The sample was eluted with the matrix a-cyano-4-hydroxycinnamic acid (5 mg/ ml) in 50% acetonitrile/0.1% TFA and spotted onto a stainless steel 192-well MALDI plate. After sample crystallization, mass spectrum acquisition was performed using a 4700 Proteomics Analyzer MALDI-TOF/TOF (Applied Biosystems, USA). Mass spectra were acquired in positive linear mode for 1-15 kDa (m/z) mass window and in positive reflector mode for the ranges 700-7000, 4000-5000, and 4585-4600 Da (m/z). External calibration of the mass spectrum was performed using Applied Biosystems Calibration Mix 3 standards.
Antibacterial activity
The antibacterial activity of the pure peptide was quantified in 96-well polypropylene microtiter plates, as described by Vogt et al., 23 with some modifications. E. coli strain K12 was grown at 37 C in LB medium until mid-logarithmic phase (OD 600 0.5). The cells were then resuspended in LB at 2 Â 10 7 and 2 Â 10 6 cells/ml; 100 ll of peptides, at different concentrations, were inoculated with 100 ll of bacterial suspension, incubated overnight at 37 C and the bacterial growth was assessed by the measurement of optical density at 620 nm. Each assay was repeated three times, using as reference sterile deionized water instead of the peptide solutions.
Results and Discussion
Expression and purification of recombinant protein
The antimicrobial peptide MAG2 was successfully cloned at the N-terminal of the LK-CBM3 in the expression vector pET-21a. After transformation of the recombinant plasmid into E. coli BL21 (DE3), several fermentation conditions, including induction temperature (18, 25, 30, and 37 C), IPTG concentration (0.1, 0.5, and 1 mM), induction time (4 h and overnight), OD 595 nm at the induction (0.4 and 0.6) were tested, attempting to optimize the production of the recombinant protein in the soluble form. The fusion protein MAG2-LK-CBM3 ($24 kDa) was successfully expressed in soluble form after induction at 37 C with 1 mM IPTG (Figure 2) . Two bands that may correspond to the expressed proteins after induction were observed, either in soluble and insoluble fractions; however, according to the purification results (Figure 3) , the recombinant MAG2-LK-CBM3 corresponds to the band with higher molecular weight (indicated with an arrow in Figure 2 ), therefore only a small amount of fusion protein was expressed under insoluble form.
There are two major problems in the expression of AMPs in E. coli: the cytoxicity of the peptides to the host and the sensitivity of peptides with positively charged amino acids to proteases. A common strategy for the production of recombinant peptides involves genetic attachment to a well expressed protein to generate a fusion protein. The protein acts to protect the peptide from proteolytic digestion and can protect the host from potential toxicity associated with some peptides. The high toxicity of the peptides usually leads to expression in inclusions bodies or in aggregate form. To overcome this situation, the use of a fusion partner is highly recommended. There are a number of fusion partner proteins available that differ in size and properties; some facilitate soluble expression while others promote the formation of inclusion bodies. [24] [25] [26] Guerreiro et al. 17 reported the soluble expression of the family 3 CBM from C. thermocellumalso used in this work-fused to three different AMPs: LKLLKKL, LKKLLKKLKKLLKK, and porcine myeloid antibacterial peptide-23 (PMAP-23) RIIDLLWRVRRPQKPK FVTVWVR. Only the protein LKLLKKLLKLLKKLGG GK-LK-CBM3 was found to be insoluble when expressed by different E. coli strains, under a range of induction conditions. Also, the constructs with CBM fused to the human cathalicidin LL37 have been previously successfully expressed in our group. 27, 28 Therefore, although the solubility of AMPs fused to the CBM3 is rather unpredictable, the expression of the fusion proteins was, in all cases, successful. In this work, the expression of soluble magainin-2, fused at the N-terminus of LK-CBM3, was achieved. The family 3 cellulose-binding module was chosen as fusion partner considering the previously demonstrated successful overexpression of several CBM-AMPs, the simplicity of purification using cellulose as an affinity chromatography matrix, and also the low cost of cellulose, which makes this an attractive purification matrix, therefore we explored the recovery of the MAG2-LK-CBM3 using cellulose CF11 fibers. As demonstrated by Tomme et al., CBM3 binds cellulose with high affinity. In fact, the equilibrium affinity constant (K a ) for Avicel was reported to be 7.7 Â 10 6 M À1 . 29 Figure  3 shows that the fusion of the peptide MAG2 did not affect the binding to cellulose. However, unlike the recombinant protein described in the works listed above, in the case of MAG2-LK-CBM the purification of on cellulose was not fully effective due to unspecific binding of contaminating proteins, and we therefore explored purification using IMAC system by exploiting the histidine tag. This allowed the more efficient recovery of purified fusion protein as shown in Figure 3 .
Chemical cleavage of MAG2-LK-CBM3
Formic acid was chosen for hydrolysis instead of thrombin or factor Xa proteases, to reduce production costs. After purification with cellulose, 50% formic acid was applied to cleave the AMP MAG2 from the fusion carrier, CBM3. The formic acid cleavage of MAG2 ($2.5 kDa) from the fusion partner LK-CBM3 was successful, as illustrated in Figure 4 . After hydrolysis, the mixture was lyophilized to remove the formic acid. The protein was resuspended in ultrapure water and centrifuged to remove proteins degraded by the formic acid. Figure 4 shows that a significant number of contaminants were present in the supernatant after the formic acid cleavage. Consequently, the supernatant containing the MAG2 peptide was purified by reverse-phase HPLC. The fractions corresponding to the major peaks ( Figure 5A ) were collected and the purity of the peptide was checked on 16.5% TrisTricine gel ( Figure 5B ). Mw, protein molecular weight marker; lanes 1-8, peak fractions of cleaved MAG2-LK-CBM3.
The fraction with a retention time of about 50 min (peak 7) contained the mostly pure antimicrobial peptide MAG2. Some contaminant proteins were not efficiently removed by RP-HPLC and remained present in low amounts. To confirm the purity and molecular weight of the peptide, MALDI-TOF analysis was performed ( Figure 6 ).
The peptide resulting from the hydrolysis has 24 amino acids with a C-terminal aspartic acid (MAG2-D), left by the chemical cleavage and a theoretical molecular weight of 2582 Da. The MALDI-TOF analysis confirmed the molecular weight of the recombinant peptide as well as its purity. This molecular weight indicates that the N-terminal methionine from the translation process has been cleaved. Giglione et al. 30 reported that 55-70% of mature proteins are subjected to N-terminal Met excision and this was the case with MAG2-LK-CBM3.
Antibacterial Activity of MAG2-LK-CBM3
After the successful expression and purification of MAG2, its activity was tested against E. coli K12, using different protein concentration between 62.5 and 200 lg/ml, in order to determine the MIC of recombinant MAG2. The concentration of the peptide was quantified by UV spectroscopy using the Waddell's method. 22 Figure 7 demonstrates that MAG2 has antimicrobial activity, with a MIC of about 100 lg/ml ($39 lM), a value similar to the ones found in the in the literature. [31] [32] [33] At lower concentration, MAG2 inhibited bacterial growth only partially, an effect dependent on the initial cellular density. The fusion protein MAG2-CBM3 did not show antimicrobial activity (results not shown).
The results suggest that the negatively charged C-terminal aspartic acid, left from acid cleavage, does not affect the antibacterial activity of the recombinant protein. Since, AMPs interact by electrostatic forces with the negatively charged bacterial membrane phospholipids, eventually leading to its disruption, 34 the lower net charge of the produced MAG2 (þ2) could affect is antibacterial activity, but actually this was not the case.
To date, the successful cloning, expression, and purification of the AMP Magainin-2 in bacteria has not been reported. Barrell et al. reported the successful expression of MAG2 fused to the well-known thioredox into raise antibodies. 21 However, they did not cleave and purify MAG2 from its expression partner. A Magainin analogs (MSI-344) was expressed and purified with good yields from E. coli inclusion bodies. The recombinant peptide kept its antibacterial activity. 35, 36 In a different approach, Fan and Li successfully expressed MAG2 in a mammalian cell system at high productivity and efficiency. 37 The very few works reported may indicate that it is very difficult to produce MAG2 in bacteria. Here we presented a strategy to produce active MAG2, which could be used to produce MAG2 analogs or other AMPs. One challenge with this approach is determining efficient elution conditions that do not result in contaminant proteins during purification using CF11 cellulose fibers. Improvements in peptide recovery might be achieved by combining cellulose affinity with on column cleavage followed by immobilized metal affinity chromatography to remove contaminants.
Conclusions
Some AMPs can physically attack the microbial membranes to kill microbes, even those that present antibiotic- Bacterial growth was inhibited at a concentration of 100 lg/ml (39 lM) of recombinant MAG2 to an initial cell concentration of 1x10 6 (black gray) or 1x10 5 (light gray). Results are represented as mean SD of OD600 nm. resistant mechanisms. These peptides have been the focus of increasing interest, arising as excellent candidates for new types of antibiotics. Production of peptide antibiotics at a large scale is a significant challenge for developing commercial products. Expression of recombinant AMPs is not always successful, either because of their activity to the host and/or proteolysis of the recombinant peptides during synthesis. In this work, the peptide MAG2 was successfully expressed, cleaved and purified. The isolated peptide bears antibacterial activity. The CBM3 utilization as fusion partner appears to be very effective for production and purification of AMPs.
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